Climate Change Data

Camurus AB (publ)

Climate Impact & Sustainability Data (2022, 2023)

Reporting Period: 2022

Environmental Metrics

Total Carbon Emissions:221.6 tCO2e/year (Scope 1 & 2 & partial Scope 3)
Scope 1 Emissions:162.4 tCO2e/year
Scope 2 Emissions:8.9 tCO2e/year
Scope 3 Emissions:60.3 tCO2e/year (partial)
Renewable Energy Share:85%
Total Energy Consumption:989 MWh/year
Water Consumption:4,730 m3/year
Waste Generated:3.6 tons/year (headquarters, incl. lab)

ESG Focus Areas

  • Patients
  • People
  • Planet
  • Responsible business

Environmental Achievements

  • Reduced product manufacturing waste by an unspecified percentage (goal of 20% reduction by 2026)
  • Increased the use of packaging material originating from sustainable sources to 29% (goal of 50% by 2026)
  • Reduced Scope 1 and 2 emissions by an unspecified amount (goal of 50% reduction from 2023 to 2026)
  • Reduced selected Scope 3 emissions by an unspecified amount (goal of 20% reduction from 2023 to 2026)

Social Achievements

  • Launched a quarterly Value Award to recognize employee contributions
  • Implemented an updated sustainability strategy and new goals
  • Conducted employee surveys showing high eNPS scores and positive feedback on work environment
  • Conducted a gender pay equality analysis with no required actions
  • Implemented a whistleblowing procedure and digital platform
  • Donated Buvidal to Ukraine

Governance Achievements

  • Implemented an updated sustainability strategy, sustainability policy, environmental policy, anti-corruption policy, and Vendor Code of Conduct
  • Recruited a Director Sustainability and a Head of Compliance
  • Formed a cross-functional Sustainability Committee
  • Provided training on Code of Conduct, Anti-Corruption, and Data Protection

Climate Goals & Targets

Long-term Goals:
  • More than 100,000 patients in treatment with Buvidal by 2026
Medium-term Goals:
  • Reduce Scope 1 and 2 emissions by 50% from 2023 to 2026
  • Reduce selected Scope 3 emissions by 20% from 2023 to 2026
  • Bring at least one new medicine to regulatory approval and market
Short-term Goals:
  • Reduce product manufacturing waste by 20% by 2026
  • Increase use of sustainable packaging materials to 50% by 2026
  • Annually conduct at least one project focused on reducing stigma for patients

Environmental Challenges

  • Supply chain disruptions due to the COVID-19 pandemic and the war in Ukraine
  • Competition in the pharmaceutical industry
  • Regulatory hurdles for new drug approvals
  • Climate change related physical and transition risks
  • Potential for human rights breaches in the supply chain
  • Risks of corruption and unethical behavior
Mitigation Strategies
  • Active risk management process
  • Collaboration with partners and licensees
  • Continuous monitoring of regulatory requirements
  • Implementation of a robust compliance framework
  • Development of a Vendor Code of Conduct and supplier follow-up
  • Implementation of a whistleblowing system
  • ESG strategy with clear goals and KPIs

Supply Chain Management

Supplier Audits: 35% of Camurus total purchases assessed with respect to sustainability risks in 2022

Responsible Procurement
  • Vendor Code of Conduct

Climate-Related Risks & Opportunities

Physical Risks
  • Increasing costs, lower availability, or disruptions of energy, logistics, materials, goods, and services due to climate change
Transition Risks
  • Carbon taxes, carbon pricing, and changes in customer preferences

Reporting Standards

Frameworks Used: GRI, SASB, OECD Guidelines for Multinational Enterprises

Third-party Assurance: PricewaterhouseCoopers AB

UN Sustainable Development Goals

  • Goal 3: Good Health and Well-being
  • Goal 8: Decent Work and Economic Growth
  • Goal 10: Reduced Inequalities
  • Goal 12: Responsible Consumption and Production
  • Goal 13: Climate Action

Camurus' initiatives contribute to these goals through improved access to treatment, sustainable business practices, and reduced environmental impact.

Sustainable Products & Innovation

  • Buvidal (long-acting formulation reducing environmental impact)

Reporting Period: 2023

Environmental Metrics

Total Carbon Emissions:561.8 tCO2e (market-based); 556 tCO2e (location-based)
Scope 1 Emissions:158.9 tCO2e
Scope 2 Emissions:17.48 tCO2e (market-based); 11.68 tCO2e (location-based)
Scope 3 Emissions:385.6 tCO2e
Renewable Energy Share:95%
Total Energy Consumption:973 MWh
Water Consumption:4,005 m3
Waste Generated:6.7 tons (hazardous waste from own operations); 22.1 tons (hazardous waste from outsourced manufacturing)
Carbon Intensity:0.007 tCO2e/SEK (market-based); 0.007 tCO2e/SEK (location-based)

ESG Focus Areas

  • Patients
  • People
  • Planet
  • Responsible Business

Environmental Achievements

  • Reduced water consumption in manufacturing by 20% compared to 2022.
  • Reduced hazardous waste generated in Camurus’ own operations by 29% compared to 2022.
  • 95% of all energy used comes from renewable sources.

Social Achievements

  • Improved employee survey engagement results for the third consecutive year.
  • Development and implementation of diversity, equity and inclusiveness (DEI) policy.
  • Launched a stigma charter to help raise awareness and challenge stigma around drug dependence.
  • Access All Areas initiative in the UK, training approximately 500 healthcare professionals and decision-makers.

Governance Achievements

  • Implementation of vendor sustainability risk management process.
  • Updated Code of Conduct and Vendor Code of Conduct.
  • Implementation of a sustainability management system based on the ISO 14001 standard.
  • Improved ESG rating results.

Climate Goals & Targets

Long-term Goals:
  • Net zero greenhouse gas emissions (scope 1, 2 and 3) by 2045.
Medium-term Goals:
  • 15% of vacancies filled internally; Employee turnover below 10%; 100% of employees have access to relevant digital training; 100% of employees complete diversity training.
Short-term Goals:
  • Reduce scope 1 and 2 greenhouse gas emissions by at least 50% by 2035.
  • Reduce selected scope 3 greenhouse gas emissions by at least 40% by 2035.

Environmental Challenges

  • Supply chain transparency and traceability.
  • Emerging carbon pricing.
  • Supply disruption or delay due to climate change.
  • Damage to premises due to extreme weather.
  • Emissions/releases to the environment.
  • Understanding of GHG emissions throughout the value chain.
  • Difficulties finding and attracting the right competencies.
  • Work safety risks.
  • Corruption and bribery in relation to healthcare interactions.
Mitigation Strategies
  • Developed a vendor sustainability risk management system.
  • Regularly monitor the effects of climate change.
  • Ensure deficiency management plans and safety stock levels are in place.
  • Regularly monitor and assess the manufacturing vendor’s safety procedures.
  • Continue environmental mapping of Camurus’ value chain.
  • Proactive recruitment and succession planning.
  • Strengthened the Business Ethics & Compliance framework.
  • Utilize systems support to ensure standardization and automatization of controls.

Supply Chain Management

Supplier Audits: 2 completed supplier follow-up environmental audits in 2023

Responsible Procurement
  • Vendor Code of Conduct
  • Sustainable procurement policy

Climate-Related Risks & Opportunities

Physical Risks
  • Supply disruption or delay due to severe weather events.
  • Damage to premises due to flooding and storms.
Transition Risks
  • Emerging carbon pricing.
Opportunities
  • GHG emission reductions due to improved access to renewable energy and transition to electric car fleet.
  • Increased, comprehensive climate-related legislation in the EU.

Reporting Standards

Frameworks Used: GRI, SASB, OECD

Certifications: ISO 14001

Third-party Assurance: PricewaterhouseCoopers AB

UN Sustainable Development Goals

  • Not disclosed

Not disclosed

Sustainable Products & Innovation

  • Buvidal
  • Brixadi
  • CAM2029

Awards & Recognition

  • Not disclosed